Literature DB >> 10897764

[Dosimetric evaluation of conformal radiotherapy: conformity factor].

R Oozeer1, B Chauvet, R Garcia, C Berger, C Felix-Faure, F Reboul.   

Abstract

The aim of three-dimensional conformal therapy (3DCRT) is to treat the Planning Target Volume (PTV) to the prescribed dose while reducing doses to normal tissues and critical structures, in order to increase local control and reduce toxicity. The evaluation tools used for optimizing treatment techniques are three-dimensional visualization of dose distributions, dose-volume histograms, tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP). These tools, however, do not fully quantify the conformity of dose distributions to the PTV. Specific tools were introduced to measure this conformity for a given dose level. We have extended those definitions to different dose levels, using a conformity index (CI). CI is based on the relative volumes of PTV and outside the PTV receiving more than a given dose. This parameter has been evaluated by a clinical study including 82 patients treated for lung cancer and 82 patients treated for prostate cancer. The CI was low for lung dosimetric studies (0.35 at the prescribed dose 66 Gy) due to build-up around the GTV and to spinal cord sparing. For prostate dosimetric studies, the CI was higher (0.57 at the prescribed dose 70 Gy). The CI has been used to compare treatment plans for lung 3DCRT (2 vs 3 beams) and prostate 3DCRT (4 vs 7 beams). The variation of CI with dose can be used to optimize dose prescription.

Entities:  

Mesh:

Year:  2000        PMID: 10897764     DOI: 10.1016/s1278-3218(00)89096-4

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  9 in total

1.  Bridging the gap between IMRT and VMAT: dense angularly sampled and sparse intensity modulated radiation therapy.

Authors:  Ruijiang Li; Lei Xing
Journal:  Med Phys       Date:  2011-09       Impact factor: 4.071

2.  Improving IMRT delivery efficiency with reweighted L1-minimization for inverse planning.

Authors:  Hojin Kim; Stephen Becker; Rena Lee; Soonhyouk Lee; Sukyoung Shin; Emmanuel Candès; Lei Xing; Ruijiang Li
Journal:  Med Phys       Date:  2013-07       Impact factor: 4.071

3.  Dose optimization with first-order total-variation minimization for dense angularly sampled and sparse intensity modulated radiation therapy (DASSIM-RT).

Authors:  Hojin Kim; Ruijiang Li; Rena Lee; Thomas Goldstein; Stephen Boyd; Emmanuel Candes; Lei Xing
Journal:  Med Phys       Date:  2012-07       Impact factor: 4.071

4.  Dosimetric impact of tumor bed delineation variability based on 4DCT scan for external-beam partial breast irradiation.

Authors:  Bing Guo; Jianbin Li; Wei Wang; Fengxiang Li; Yanluan Guo; Yankang Li; Tonghai Liu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

5.  Impact of dose calculation accuracy during optimization on lung IMRT plan quality.

Authors:  Ying Li; Anna Rodrigues; Taoran Li; Lulin Yuan; Fang-Fang Yin; Q Jackie Wu
Journal:  J Appl Clin Med Phys       Date:  2015-01-08       Impact factor: 2.102

6.  Conformity Index and Homogeneity Index of the Postoperative Whole Breast Radiotherapy.

Authors:  Deva Petrova; Snezana Smickovska; Emilija Lazarevska
Journal:  Open Access Maced J Med Sci       Date:  2017-09-17

7.  Correlation between target motion and the dosimetric variance of breast and organ at risk during whole breast radiotherapy using 4DCT.

Authors:  Wei Wang; Jian Bin Li; Hong Guang Hu; Feng Xiang Li; Min Xu; Tao Sun; Jie Lu
Journal:  Radiat Oncol       Date:  2013-05-02       Impact factor: 3.481

8.  Evaluation of dosimetric variance in whole breast forward-planned intensity-modulated radiotherapy based on 4DCT and 3DCT.

Authors:  Wei Wang; Jian Bin Li; Hong Guang Hu; Tao Sun; Min Xu; Ting Yong Fan; Qian Shao
Journal:  J Radiat Res       Date:  2013-01-24       Impact factor: 2.724

9.  Unified dosimetry index (UDI): a figure of merit for ranking treatment plans.

Authors:  Hilary Akpati; ChangSeon Kim; Bong Kim; Tae Park; Allen Meek
Journal:  J Appl Clin Med Phys       Date:  2008-06-23       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.